ClinicalTrials.gg
RecruitingNCT07273019TMAC-CUpdated Jul 30, 2026

Tongue Muscular Assessment in Children With Sleep Disordered Breathing

An interventional study of Tongue Strength Assessment and Polysomnography in Obstructive Sleep Apnea, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon — 6 open to participants now, 7 under way, none of them phase 3. Sleep Apnea, Obstructive · Hospices Civils de Lyon.

Started
2026
with 5 others
No phase
7 of 11
4 open now
Registered
8th of 11
by date

Among the 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon, this one is one of 6 that started in 2026, is one of 7 with no phase, and was the 8th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is part of the sleep-disordered breathing spectrum. Its prevalence in children is 1-5%, and it can have negative consequences at the cardiovascular, cognitive as well as behavioral levels. In children, the first-line treatment is adenotonsillectomy. However, residual obstructive events can persist as the success rate of surgery reaches only 49% in non-obese children. Residual OSA may be explained by multiple sites of obstruction, found in 20-85% children concerned by persistent OSA. Indeed, the tongue appears among one possible primary sites of obstruction. Given the tongue's crucial role in upper-airway patency during sleep, its assessment can inform us about the myofunctional deficits involved in sleep-disordered breathing.

The primary objective of the present study is to assess tongue motor functions in children with sleep-disordered breathing and to compare them to those of healthy children (data collected in a current study (TMAC) conducted at UCLouvain, Belgium; NCT06166680), in order to document possible myofunctional deficits in children with OSA. The hypothesis is that tongue motor functions will be lower in children with sleep-disordered breathing.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Tongue
  • Motor functions
  • Sleep
  • Sleep apnea
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With suspected sleep-disordered breathing
  • Referred for polysomnography
  • Affiliated to a social security scheme
  • With from both legal representatives

Exclusion criteria

Exclusion Criteria:

  • Insufficient comprehension of French language
  • Regarding patients with suspected OSA type I or II:

    • Neurological, cardiac, or unstable respiratory conditions other than sleep disorders and their repercussions
    • Any deficit possibly impacting measurements according to the investigator (e.g., psychiatric condition)
    • Malformation of the skull, the upper airway or the oral cavity
  • Regarding patients with suspected OSA type III:

    • Any deficit possibly impacting measurements according to the investigator (e.g., psychiatric condition)
    • Intellectual deficit impeding the understanding of instructions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Children referred for polysomnography for suspected OSA

    Children aged 4 to 17 years old, referred to the sleep clinic for polysomnography in a context of suspected OSA

    Other: Tongue Strength Assessment · Diagnostic Test: Polysomnography · Other: Subjective Assessment of Sleep-Disordered Breathing · Other: Subjective Assessment of Daytime Functioning · Other: Anthropometry · Other: Clinical Examination · Other: Orofacial Praxis Assessment

Interventions

  • OtherTongue Strength Assessment

    The following items will be assessed: 1. Tongue peak pressure during 3 seconds of tongue protrusion 2. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 seconds of tongue elevation 3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing

  • Diagnostic testPolysomnography

    Patients will undergo full-night polysomnography (including the JAWAC system to record mandibular movements) in the sleep unit of Hôpital Femme-Mère-Enfant (Bron, France) to explore OSA.

  • OtherSubjective Assessment of Sleep-Disordered Breathing

    The following questionnaires will be filled out: * OSA-18 * Pediatric Sleep Questionnaire (PSQ) * Spruyt \& Gozal * Sleep Disturbance Scale for Children * Abreu et al.'s questionnaire

  • OtherSubjective Assessment of Daytime Functioning

    The following questionnaires will be filled out: * Epworth Sleepiness Scale * Conners

  • OtherAnthropometry

    The following measures will be collected via the Quick Tongue-Tie Assessment tool: 1. Maximal mouth opening 2. Maximal mouth opening with tongue to palate

  • OtherClinical Examination

    The following variables will be collected during a clinical examination: 1. Age 2. Sex 3. Weight 4. Height 5. BMI 6. Friedman score 7. Mallampati score 8. Medical history

  • OtherOrofacial Praxis Assessment

    Bucco-Linguo-Facial Motor Skills will be assessed through the test "Motricité Bucco-Linguo-Faciale" (MBLF).

06

What researchers measure

Primary outcomes

  1. Tongue peak pressure during protrusion

    Tongue peak pressure during protrusion will be measured using the IOPI (Iowa Oral Performance Instrument) device. Higher tongue pressure is considered a better outcome.

    Time frame: Day 1

Secondary outcomes

  1. Tongue peak pressure during elevation and swallowing

    Tongue peak pressure during elevation and swallowing movements will be measured using the IOPI (Iowa Oral Performance Instrument) device. Higher tongue pressure is considered a better outcome.

    Time frame: Day 1

  2. Tongue mobility restriction

    Assessed through the ratio between maximal mouth opening and maximal mouth opening with tongue to palate, measured using the Quick Tongue-Tie Assessment tool. Higher values are considered a better outcome.

    Time frame: Day 1

  3. Orofacial praxis

    Orofacial praxis will be assessed through the Motricité Bucco-Linguo-Faciale (MBLF) test, which ranges from 0 to 111. Higher scores indicate a better outcome.

    Time frame: Day 1

  4. Obstructive apnea-hypopnea index (OAHI)

    Respiratory parameters will be assessed by night polysomnography. A higher index indicates a worse outcome.

    Time frame: Day 1

  5. Central apnea-hypopnea index

    Respiratory parameters will be assessed by night polysomnography. A higher index indicates a worse outcome.

    Time frame: Day 1

  6. Mixed apnea-hypopnea index

    Respiratory parameters will be assessed by night polysomnography. A higher index indicates a worse outcome.

    Time frame: Day 1

  7. Respiratory effort index

    Respiratory parameters will be assessed by night polysomnography. A higher index indicates a worse outcome.

    Time frame: Day 1

  8. Respiratory effort-related arousal index (RERA)

    Respiratory parameters will be assessed by night polysomnography. A higher index indicates a worse outcome.

    Time frame: Day 1

  9. Mean CO2

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  10. Max CO2

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  11. Time spent with CO2 > 50mmHg

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  12. Mean SpO2

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  13. Desaturation index ≥ 3%

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  14. Desaturation index ≥ 4%

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  15. Time spent with SaO2 < 90%

    Respiratory parameters will be assessed by night polysomnography.

    Time frame: Day 1

  16. Total sleep time

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  17. Sleep onset latency

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  18. Wake after sleep onset

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  19. Duration of sleep N1

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  20. Duration of sleep N2

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  21. Duration of sleep N3

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  22. Duration of REM sleep

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  23. Sleep efficiency

    Sleep architecture parameters will be assessed by night polysomnography.

    Time frame: Day 1

  24. Score on Abreu's Questionnaire

    Total score ranges from 0 to 16. Higher scores indicate a worse outcome.

    Time frame: Day 1

  25. Score on the OSA-18 Questionnaire

    This questionnaire assesses quality of life associated with sleep-disordered breathing in children. Total score ranges from 18 to 126. Higher scores indicate a worse outcome.

    Time frame: Day 1

  26. Score on the Pediatric Sleep Questionnaire

    This questionnaire assesses symptoms and repercussions of sleep-disordered breathing in children. Total score ranges from 0 to 22. Higher scores indicate a worse outcome.

    Time frame: Day 1

  27. Score on the Spruyt & Gozal Questionnaire

    This questionnaire assesses sleep-disordered breathing in children. Total score ranges from 0 to 4. Higher scores indicate a worse outcome.

    Time frame: Day 1

  28. Score on the Sleep Disturbance Scale for Children

    This questionnaire assesses sleep disturbance in children. Total score ranges from 25 to 125. Higher scores indicate a worse outcome.

    Time frame: Day 1

  29. Score on the French Version of the Sleepiness Scale for Adolescents

    This questionnaire assesses excessive daytime sleepiness. Total score ranges from 25 to 125. Higher scores indicate a worse outcome.

    Time frame: Day 1

  30. Score on the Conners Rating Scale

    This questionnaire assesses hyperactivity. Total score ranges from 0 to 30. Higher scores indicate a worse outcome.

    Time frame: Day 1

  31. Medical history

    Medical history is conducted by a doctor. It will be used to determine the type of OSA (craniofacial and/or syndromic comorbidities classify OSA as type III; otherwise, OSA is type II in the presence of obesity, or type I in the absence of obesity).

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 9, 2025
StartActual
Mar 26, 2026
Primary completionEst.
Mar 26, 2028
CompletionEst.
Mar 26, 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273019
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Mar 26, 2026
Primary completion
Mar 26, 2028 (estimated)
Completion
Mar 26, 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Patricia FRANCO, MD, PhD
Contact
patricia.franco@chu-lyon.fr
+33 4 27 85 60 52
Aurore GUYON, PhD
Contact
aurore.guyon@chu-lyon.fr
+33 4 27 85 52

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion